

(use as many sheets as necessary)

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1614
Examiner Name	LESLIE A. ROYDS
Attorney Docket Number	13131-0292 (44378-287574)

Sheet	1	of	3
-------	---	----	---


[illegible]

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
UAR	13	WO	99/38498	A1	Warner-Lambert Company	08-05-1999	-
UAR	14	WO	01/56579	A1	Esperion Therapeutics, Inc.	08-09-2001	-
UAR	15	WO	02/10768	A3	The Regents of the University of California	02-07-2002	-
UAR	16	WO	02/30863	A2	Esperion Therapeutics, Inc.	04-18-2002	-
UAR	17	WO	02/062824	A3	Andrx Corporation	08-15-2002	-

Date
Considered

16 JULY 07

Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.



Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1614
Examiner Name	LESLIE A. ROYDS
Attorney Docket Number	13131-0292 (44378-287574)

Sheet 2 of 3

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
NAE	18	BARRES, BEN A., et al., Cholesterol - Making or Breaking the Synapse, Science, November 9, 2001, pp. 1296-1297, vol. 294.	
NAE	19	BURNS, M. et al., Use of in vivo Models to Study the Role of Cholesterol in the Etiology of Alzheimer's Disease, Neurochem Res, July 2003, pp. 979-86 (abstract only), vol. 28.	
NAE	20	COOPER, J., Dietary Lipids in the Aetiology of Alzheimer's Disease: Implications for Therapy, Drugs Aging, 2003, pp. 399-418 (abstract only), vol. 20, no. 6.	
NAE	21	GLODE, TODD E., et al., Cholesterol Modulation as an Emerging Strategy for the Treatment of Alzheimer's Disease, Drug Discovery Today, Oct. 15, 2001, pp. 1049-1055 (abstract only), vol. 6, no. 20.	
NAE	22	KOUDINOV, A.R., et al., Alzheimer's Amyloid Beta Interaction with Normal Human Plasma High Density Lipoprotein: Association with Apolipoprotein and Lipids, Clin Chim Acta, February 23, 1998, pp. 75-84 (abstract only), vol. 270, no. 2.	
NAE	23	KOUDINOV, A.R., et al., Alzheimer's Soluble Amyloid Beta Protein is Secreted by HepG2 Cells as an Apolipoprotein, Cell Biol Int., May 1997, pp. 265-71 (abstract only), vol. 21, no. 5.	
NAE	24	KOUDINOV, A.R., et al., Biochemical Characterization of Alzheimer's Soluble Amyloid Beta Protein in Human Cerebrospinal Fluid: Association with High Density Lipoproteins, Biochem Biophys Res Commun., June 25, 1996, pp. 592-7 (abstract only), vol. 223, no. 3.	
NAE	25	KOUDINOV, ALEXEI R., et al., Cholesterol's Role in Synapse Formation, Science, November 9, 2001, pp. 2213, vol. 294.	
NAE	26	KOUDINOVA, N.V., et al., Amyloid Beta, Neural Lipids, Cholesterol and Alzheimer's Disease, Soc. Neuroscience Abstract Viewer and Itinerary Planner, Nov: 2-7, 2002, pp. Abstract No. 21.10, vol. 2002.	
NAE	27	LIPID SCIENCES, Lipid Technology, http://www.lipidsciences.com/technology.html , August 25, 2001, pp. 1-4.	
NAE	28	MAUCH, DANIELA H., et al., CNS Synaptogenesis Promoted by Gila-Derived Cholesterol, Science, November 9, 2001, pp. 1354-1357, vol. 294.	
NAE	29	REFOLO, L.M., et al, Cholesterol Metabolism: A Potential Target for Alzheimer's Disease Therapy, Soc. Neuroscience Abstracts, 2001, pp. 1518, vol. 27, no. 2.	
NAE	30	YOSHIDOME, HIROAKI et al., Serum Amyloid A and P Protein Levels are Lowered by Dextran Sulfate Cellulose Low-Density Lipoprotein Apheresis, Artif Organs, 1998, pp 144-148, vol. 22, no. 2.	

Examiner
SignatureDate
Considered

16 JULY 07

Unique citation designation number. Applicant is to place a check mark here if English language translation is attached.



PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1614
Examiner Name	LESLIE A. ROYDS
Attorney Docket Number	13131-0292 (44378-287574)

Sheet 3 of 3


OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LAR	31	Zetia (ezetimibe), http://www.zetia.com/ezetimibe/zetia/hcp/product_highlights/index.jsp , July 18, 2003, pp. 1-2.	
LAR	32	Zetia: Complements Statin with a Unique Mechanism, http://www.zetia.com/ezetimibe/zetia/hcp/mechanism_of_action/index.jsp , July 18, 2003, pp. 1-2..	

Examiner
SignatureDate
Considered

16 JULY 07

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1646-1614
Examiner Name	Not yet Assigned LESLIE A. ROYDS
Attorney Docket Number	13131-0292 (44378/287574)

Sheet 1 of 9

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document ²	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code ³ (if known)				
WAL	1	3,647,624		Evenson	03-07-1972		
WAL	2	3,958,939		Jones	05-25-1976		
WAL	3	3,983,008		Shinozaki et al.	09-28-1976		
WAL	4	3,989,466		Pan	11-02-1976		
WAL	5	4,025,423		Stonner et al.	05-24-1977		
WAL	6	4,103,685		Lupien et al.	08-01-1978		
WAL	7	4,124,509		Iijima et al.	11-07-1978		
WAL	8	4,234,317		Lucas et al.	11-18-1980		
WAL	9	4,235,602		Meyer et al.	11-25-1980		
WAL	10	4,258,010		Rozsa et al.	03-24-1981		
WAL	11	4,350,156		Malchesky et al.	09-21-1982		
WAL	12	4,391,711		Jackson et al.	07-05-1983		
WAL	13	4,399,217		Holmquist et al.	08-16-1983		
WAL	14	4,402,940		Nose et al.	09-16-1983		
WAL	15	4,435,289		Breslau	03-06-1984		
WAL	16	4,463,988		Bouck et al.	08-07-1984		
WAL	17	4,481,189		Prince	11-06-1984		
WAL	18	4,522,809		Adamowicz et al.	06-11-1985		
WAL	19	4,540,401		Marten	09-10-1985		
WAL	20	4,540,573		Neurath et al.	09-10-1985		
WAL	21	4,591,505		Prince	05-27-1986		
WAL	22	4,613,501		Horowitz	09-23-1986		
WAL	23	4,615,886		Purcell et al.	10-07-1986		
WAL	24	4,643,718		Marten	02-17-1987		
WAL	25	4,645,512		Johns	02-24-1987		
WAL	26	4,647,280		Maaskant et al.	03-03-1987		
WAL	27	4,648,974		Roskopf et al.	03-10-1987		
WAL	28	4,668,398		Silvis	05-26-1987		
WAL	29	4,671,909		Torobin	09-09-1987		
WAL	30	4,676,905		Nagao et al.	06-30-1987		
WAL	31	4,677,057		Curtiss et al.	06-30-1987		
WAL	32	4,680,320		Uku et al.	07-14-1987		
WAL	33	4,696,670		Ohnishi et al.	09-29-1987		
WAL	34	4,775,483		Mookerjee et al.	10-04-1988		
WAL	35	4,832,034		Pizziconi et al.	05-23-1989		
WAL	36	4,836,928		Aoyagi et al.	06-06-1989		
WAL	37	4,879,037		Utzinger	11-07-1989		

Examiner
SignatureDate
Considered

16 JULY 07

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

IDS Filed Aug. 18, 2004

PTO/SB/08A (08-00)


Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/650,110
		Filing Date	August 26, 2003
		First Named Inventor	Yanhong Zhu
		Group Art Unit	1646 1614
		Examiner Name	Not yet Assigned LESLIE A. RYDGS
Sheet 2	of 9	Attorney Docket Number	13131-0292 (44378/287574)

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
LAR	38	4,895,558		Cham	01-23-1990	
LAR	39	4,908,354		Seidel et al.	03-13-1990	
LAR	40	4,909,940		Horowitz et al.	03-20-1990	
LAR	41	4,909,942		Sato et al.	03-20-1990	
LAR	42	4,923,439		Seidel et al.	05-08-1990	
LAR	43	4,935,204		Seidel et al.	06-19-1990	
LAR	44	4,966,709		Nose et al.	10-30-1990	
LAR	45	4,970,144		Fareed et al.	11-13-1990	
LAR	46	5,026,479		Bikson et al.	06-25-1991	
LAR	47	5,080,796		Nose et al.	01-14-1992	
LAR	48	5,089,602		Islaker et al.	02-18-1992	
LAR	49	5,112,956		Tang et al.	05-12-1992	
LAR	50	5,116,307		Collins	05-26-1992	
LAR	51	5,126,240		Curtiss	03-30-1992	
LAR	52	5,128,318		Levine et al.	07-07-1992	
LAR	53	5,152,743		Gorsuch et al.	10-06-1992	
LAR	54	5,187,010		Parham et al.	02-16-1993	
LAR	55	5,203,778		Boehringer	04-20-1993	
LAR	56	5,211,850		Shettigar et al.	05-18-1993	
LAR	57	5,236,644		Parham et al.	08-17-1993	
LAR	58	5,256,767		Salk et al.	10-26-1993	
LAR	59	5,258,149		Parham et al.	11-02-1993	
LAR	60	5,279,540		Davidson	01-18-1994	
LAR	61	5,301,694		Raymond et al.	04-12-1994	
LAR	62	5,354,262		Boehringer et al.	10-11-1994	
LAR	63	5,391,143		Kensey	02-21-1995	
LAR	64	5,393,429		Nakayama et al.	02-28-1995	
LAR	65	5,401,415		Rauh et al.	03-28-1995	
LAR	66	5,401,466		Foltz et al.	03-28-1995	
LAR	67	5,418,061		Parham et al.	05-23-1995	
LAR	68	5,419,759		Naficy	05-30-1995	
LAR	69	5,424,068		Filip	06-13-1995	
LAR	70	5,476,715		Otto	12-19-1995	
LAR	71	5,484,396		Naficy	01-16-1996	
LAR	72	5,496,637		Parham et al.	03-05-1996	
LAR	73	5,523,096		Okarma et al.	06-04-1996	
LAR	74	5,634,893		Rishton	06-03-1997	
LAR	75	5,637,224		Sirkar et al.	06-10-1997	

Examiner Signature		Date Considered	16 JULY 07
--------------------	---	-----------------	------------

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

IDS Filed Aug. 18, 2004

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1646 1614
Examiner Name	Not yet Assigned LESUEA RONDY
Attorney Docket Number	13131-0292 (44378/287574)

Sheet 3 of 9

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code ² (if known)				
LAL	76	5,652,339		Lerch et al.	07-29-1997		
NAL	77	5,679,260		Boos et al.	10-21-1997		
LAL	78	5,698,432		Oxford	12-16-1997		
LAR	79	5,707,673		Prevost et al.	01-13-1998		
LAL	80	5,719,194		Mann et al.	02-17-1998		
LAL	81	5,744,038		Cham	04-28-1998		
LAL	82	5,753,227		Strahilevitz	05-19-1998		
LAL	83	5,853,725		Salk et al.	12-29-1998		
LAL	84	5,855,782		Falkenhagen et al.	01-05-1999		
LAL	85	5,858,238		McRea et al.	01-12-1999		
LAL	86	5,877,005		Castor	03-02-1999		
LAL	87	5,885,578		Salk et al.	03-23-1999		
LAL	88	5,895,650		Salk et al.	04-20-1999		
LAL	89	5,911,698		Cham	06-15-1999		
LAL	90	5,916,806		Salk et al.	06-29-1999		
LAL	91	5,919,369		Ash	07-06-1999		
LAL	92	5,928,930		Salk et al.	07-27-1999		
LAL	93	5,948,441		Lenk et al.	09-09-1999		
LAL	94	5,962,322		Kozarsky et al.	10-05-1999		
LAL	95	5,980,478		Gorsuch et al.	11-09-1999		
LAL	96	6,004,925		Dasseux et al.	12-21-1999		
LAL	97	6,017,543		Salk et al.	01-25-2000		
LAL	98	6,022,333		Kensev	02-28-2000		
LAL	99	6,037,323		Dasseux et al.	03-14-2000		
LAL	100	6,039,946		Strahilevitz	03-21-2000		
LAL	101	6,046,166		Dasseux et al.	04-04-2000		
LAL	102	6,136,321		Barrett et al.	10-24-2000		
LAL	103	6,139,746		Kopf	10-31-2000		
LAL	104	6,156,727		Garber et al.	12-05-2000		
LAL	105	6,171,373		Park et al.	01-09-2001		
LAL	106	6,193,891		Kent et al.	02-27-2001		
LAL	107	6,264,623		Strahilevitz	07-24-2001		
LAL	108	6,309,550		Iverson et al.	10-30-2001		
LAL	109	6,337,368		Kobayashi et al.	01-08-2002		
LAL	110	6,605,588		Lees et al.	08-12-2003		
LAL	111	6,706,008		Vishnoi et al.	03-16-2004		
-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-

Examiner
SignatureDate
Considered

16 JULY 07

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1646/614
Examiner Name	Not yet Assigned LESUEA. ROYDS
Attorney Docket Number	13131-0292 (44378/287574)

Sheet	4	of	9
-------	---	----	---

[illegible]

Examiner
Signature

Date Considered

16 JULY 07

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

IDS Filed Aug. 18, 2004

PTO/SB/08B (08-00)


Approved for use through 10/31/2002 OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/650,110
		Filing Date	August 26, 2003
		First Named Inventor	Yanhong Zhu
		Group Art Unit	1646/1614
		Examiner Name	Not yet Assigned LESLIE A. RONDOS
Sheet 5	of 9	Attorney Docket Number	13131-0292 (44378/287574)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LAR	129	Agnese, et al., Clinical Biochemistry, Evaluation of Four Reagents for Delipidation of Serum, 16, 98-100. (1983)	
LAR	130	Albouz, et al., Ann. Biol. Clin., Extraction of Plasma Lipids Preserving Antigenic Properties of Proteins and Allowing Quantitation of Gangliosides by Neuraminic Acid Determination, 37, 287-290. (abstract only) (1979)	
LAR	131	Andre et al., Journal of Virology, Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles, 76 (14), 6919-6928. (July 2002)	
LAR	132	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Distribution of Apo A-I-Containing HDL Subpopulations in Patients with Coronary Heart Disease, 20, 2670-2676. (December 1, 2000)	
LAR	133	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Presence and Formation of 'Free Apolipoprotein A-I-Like' Particles in Human Plasma, 15, 1419-1423. (1995)	
LAR	134	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Role of Free Apolipoprotein A-I in Cholesterol Efflux, 17, 1630-1636. (1997)	
LAR	135	Badimon, et al., Laboratory Investigation, High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in Cholesterol-Fed Rabbits, 60, 455-461. (1989)	
LAR	136	Badimon, et al., J. Clinical Investigation, Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-Fed Rabbit, 85, 1234-1241. (1990)	
LAR	137	Barrans et al., Biochimica et Biophysica Acta, Pre- β HDL: Structure and Metabolism, 1300, 73-85. (1996)	
LAR	138	Bloom, et al., Clin. Biochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human serum, 14, 119-125. (abstract only) (June 1981)	
LAR	139	Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976)	
LAR	140	Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17, 176-181. (1976)	
LAR	141	Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of α - and β -Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976)	

Examiner Signature		Date Considered	16 JULY 07
--------------------	---	-----------------	------------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

IDS Filed Aug 18, 2004

PTO/SB/08B (08-00)


Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO		Complete if Known	
		Application Number	10/650,110
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	August 26, 2003
		First Named Inventor	Yanhong Zhu
		Group Art Unit	1646 1614
		Examiner Name	Not yet Assigned LESLIE A. ROYDS
Sheet 6	of 9	Attorney Docket Number	13131-0292 (44378/287574)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LAR	142	Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	
LAR	143	Cham, et al., Chem. Biol. Interactions, Importance of Apolipoproteins in Lipid Metabolism, 20, 263-277. (1978)	
LAR	144	Cham, et al., J. Biol. Chem., In Vitro Partial Relipidation of Apolipoproteins in Plasma, 251, 6367-6371. (abstract only) (1976)	
LAR	145	Cham, et al., Pharmacol. (Life Sci. Adv.), Lipid Apheresis in an Animal Model Causes Acute Reduction in plasma Lipid Concentrations and Mobilisation of Lipid from Liver and Aorta, 13, 25-32. (1994)	
LAR	146	Cham, et al., J. Clin. Apheresis, Lipid Apheresis in an Animal Model Causes In Vivo Changes in Lipoprotein Electrophoretic Patterns, 11, 61-70. (1996)	
LAR	147	Cham, et al., J. Clin. Apheresis, Lipid Apheresis: An In Vivo Application of Plasma Delipidation with Organic Solvents Resulting in Acute Transient Reduction of Circulating Plasma Lipids in Animals, 10, 61-69. (1995)	
LAR	148	Cham, et al., Clinical Chemistry, Phospholipids in EDTA - Treated Plasma and Serum, 39, 2347-2348. (1993)	
LAR	149	Cham, et al., 59th Congress European Atherosclerosis Society, Nice, France, Rapid Regression of Atherosclerosis by Cholesterol Apheresis - A Newly Developed Technique, 17-21. (abstract only) (May 1992)	
LAR	150	Cham, et al., Clinica Chimica Acta, Rapid, Sensitive Method for the Separation of Free Cholesterol from Ester Cholesterol, 49, 109-113. (1973)	
LAR	151	Collet et al., Journal of Biological Chemistry, Differential Effects of Lecithin and Cholesterol on the Immunoreactivity and Confirmation of Apolipoprotein A-I in High Density Lipoproteins, 266 (14), 9145-9152. (May 15, 1991)	
LAR	152	Cruzado et al., Analytical Biochemistry, Characterization and Quantitation of the Apoproteins of High-Density Lipoprotein by Capillary Electrophoresis, 14 (7), 100-109. (1996)	
LAR	153	Deva, et al., J. Hosp. Infect., Establishment of an in-use testing method for evaluating disinfection of surgical instruments using the duck hepatitis B model, 22, 119-130. (abstract only) (June 1996)	
LAR	154	Dwivedy, 18th Australian Atherosclerosis Society Conference, Surfers Paradise, Increase of Reverse Cholesterol Transport by Cholesterol Apheresis Regression of Atherosclerosis, 21. (1992)	

Examiner Signature		Date Considered	16 JULY 07
--------------------	---	-----------------	------------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

IDS Filed Aug. 18, 2004

PTO/SB/08B (08-00)


Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/APTO		Complete if Known	
		Application Number	10/650,110
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	August 26, 2003
		First Named Inventor	Yanhong Zhu
		Group Art Unit	4646-1614
		Examiner Name	Not yet Assigned - LESUEA ROYDS
		Attorney Docket Number	13131-0292 (44378/287574)
Sheet	7	of	9

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LAR	155	Eisenhauer, et al, Klin Wochenschr (KWH), Selective Removal of Low Density Lipoproteins (LDL) by Precipitation at Low pH: First Clinical Application of the HELP System, 65, 161-168. (1987)	
LAR	156	Fang, et al., 18th Australian Atherosclerosis Society Conference, Gold Coast, Australia, In Vivo Rapid Mobilization of Adipose Tissue by Lipid Apheresis - A Newly Developed Technique. (1992)	
LAR	157	Feinstone, et al., Infection and Immunity, Inactivation of Hepatitis B Virus and Non-A, Non-B Hepatitis by Chloroform, 41, 816-821. (August 1983)	
LAR	158	Hatch et al., Lipoprotein Analysis, Advances in Lipid Research, Practical Methods for Plasma Lipoprotein Analysis, 6, 1-68. (1968)	
LAR	159	Horowitz, et al., Blood Coagulation and Fibrinolysis, Viral safety of solvent/detergent-treated blood products, 5, S21-S28. (1994)	
LAR	160	Innerarity, et al., Biochemistry, Enhanced Binding by Cultured Human Fibroblasts of Apo-E-Containing Lipoproteins as Compared with Low Density Lipoproteins, 17, 1440-1447. (1978)	
LAR	161	Jackson et al., Biochimica et Biophysica Acta, Isolation and Characterization of the Major Apolipoprotein from Chicken High Density Lipoproteins, 420, 342-349. (1976)	
LAR	162	Klimov, et al., Kardologia, Extraction of Lipids from Blood Plasma and Subsequent Introduction of Autologous Delipidized Plasma into the Body as a Possible Means to Treat Atherosclerosis [translation], 18, 23-29. (1978)	
LAR	163	Koizumi, et al., J. Lipid Research, Behavior of Human Apolipoprotein A-1: Phospho-Lipid and apoHDL: Phospholipid Complexes In Vitro and After Injection into Rabbits, 29, 1405-1415. (1988)	
LAR	164	Kostner, et al., XI Internet Symp. on Drugs Affecting Lipid Metabolism, Italy, Increase of APO A1 Concentration in Hypercholesterolaemic Chickens after Treatment with a Newly Developed Extracorporeal Lipid Elimination, (May 13, 1992)	
LAR	165	Kostner, et al., European Journal of Clinical Investigation, Lecithin-cholesterol acyltransferase activity in Normocholesterolaemic and Hypercholesterolaemic Roosters: Modulation by Lipid Apheresis, 27, 212-218. (May 7, 1997)	
LAR	166	Lupien, et al., Lancet (LOS), A New Approach to the Management of Familial Hypercholesterolaemia: Removal of Plasma-Cholesterol Based on the Principle of Affinity Chromatography, 1, 1261-1265. (1976)	
LAR	167	Moya et al., Arteriosclerosis and Thrombosis, A Cell Culture System for Screening Human Serum for Ability to Promote Cellular Cholesterol Efflux, 14 (7), 1056-1065. (July 1994)	

Examiner Signature		Date Considered	16 JULY 07
--------------------	---	-----------------	------------

¹Unique citation designation number, ²Applicant is to place a check mark here if English language translation is attached.

IDS Filed Aug. 18, 2004


PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO		Complete if Known	
		Application Number	10/650,110
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	August 26, 2003
		First Named Inventor	Yanhong Zhu
		Group Art Unit	1646-1614
		Examiner Name	Not yet Assigned LESUE A. ROYDS
		Attorney Docket Number	13131-0292 (44378/287574)
Sheet	8	of	9

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LAR	168	Ngu, Medical Hypotheses, Chronic Infections from the Perspective of Evolution: a Hypothesis, 42, 81-88. (1994)	
LAR	169	Ngu, Medical Hypotheses, Human Cancers and Viruses: A Hypothesis for Immune Destruction of Tumours Caused by Certain Enveloped Viruses Using Modified Viral Antigens, 39, 17-21. (1992)	
LAR	170	Ngu, Medical Hypotheses, The viral envelope in the evolution of HIV: a hypothetical approach to inducing an effective immune response to the virus, 48, 517-521. (1997)	
LAR	171	Okazaki et al., Journal of Chromatography, Biomedical Applications, Improved High-Performance Liquid Chromatographic Method for the Determination of Apolipoproteins in Serum High-Density Lipoproteins, 430, 135-142. (1988)	
LAR	172	Parker, et al., Proceedings of the National Academy of Sciences, Plasma High Density Lipoprotein is Increased in Man When Low Density Lipoprotein (LDL) is Lowered by LDL-Pheresis, 83, 777-781. (1986)	
LAR	173	Paterno et al., Department of Clinical and Experimental Medicine, Reconstituted High-Density Lipoprotein Exhibits Neuroprotection in Two Rat Models of Stroke. (December 29, 2003)	
LAR	174	Robert et al., Experientia, The Application of Sodium Deoxycholate and Sephacryl-200 for the Delipidation and Separation of High Density Lipoproteins, 38, 437-439. (1982)	
LAR	175	Ryan, et al., Clinical Chemistry, An Improved Extraction Procedure for the Determination of Triglycerides and Cholesterol in Plasma or Serum, 13, 769-772. (1967)	
LAR	176	Scanu et al., Analytical Biochemistry, Solubility in Aqueous Solutions of Ethanol of the Small Molecular Weight Peptides of the Serum Very Low Density and High Density Lipoproteins: Relevance to the Recovery Problem During Delipidation of Serum Lipoproteins, 44, 576-588. (1971)	
LAR	177	Segrest et al., Journal of Biological Chemistry, A Detailed Molecular Belt Model for Apolipoprotein A-I in Discoidal High Density Lipoprotein, 274 (45), 31755-31758. (November 5, 1999)	
LAR	178	Slater, et al., J. of Lipid Research, A Comparison of Delipidated Sera Used in Studies of Sterol Synthesis by Human Mononuclear Leukocytes, 20, 413-416. (1979)	
LAR	179	Slater, et al., Atherosclerosis, The Effect of Delipidated High Density Lipoprotein on Human Leukocyte Sterol Synthesis, 35, 41-49. (1980)	

Examiner Signature		Date Considered	16 JULY 07
--------------------	---	-----------------	------------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1646 1614
Examiner Name	Not yet Assigned LESLIE A. ROYDS
Attorney Docket Number	13131-0292 (44378/287574)

Sheet	9	of	9
-------	---	----	---


[illegible]

**Examiner
Signature**

Date
Considered

16 JULY 07

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1646 1614
Examiner Name	Unknown LESLIE A. ROYDS
Attorney Docket Number	13131-0292 (44378-287574)

[illegible][illegible]

16 JULY 07

¹Unique citation designation number. ²See attached kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

IDS Filed Sept. 5, 2006

PTO/SB/088 (08-00)

Approved for use through 10/31/2002 OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1646 1614
Examiner Name	Unknown LESLIE A. ROYDS
Attorney Docket Number	13131-0292 (44378-287574)

Sheet 2 of 2

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
LAR	9	BAROUCH et al. "Eventual AIDS Vaccine Failure in a Rhesus Monkey by Viral Escape from Cytotoxic T Lymphocytes", Nature, January 17, 2002, pps. 335-339, Vol. 415.	
LAL	10	CLAY et al., "Formation of Apolipoprotein-Specific High Density Lipoprotein Particles from Lipid-Free Apolipoproteins A-I and A-II, Biochemical Society, 1999, pps. 445-451, Vol. 337.	
LAR	11	DURBIN et al., "The Effect of Apolipoprotein A-II on the Structure and Function of Apolipoprotein A-I in a Homogeneous Reconstituted High Density Lipoprotein Particle, The Journal of Biological Chemistry", December 12, 1997, pps. 31333-31339, Volume 272, No. 50.	
LAR	12	FEINBERG et al. AIDS Vaccine Models: Challenging Challenge Viruses, Nature Medicine, March 2002, pps. 208-210, Volume 8, No. 3.	
LAR	13	FEINSTONE, et al. "Inactivation of Hepatitis B Virus and Non-A, Non-B Hepatitis by Chloroform, Infection and Immunity, August 1983, p. 816-821, Vol. 41, No. 2.	
LAR	14	WALKER, et al. "Escape from the Immune System", Nature, September 21, 2000, 313-314, Vol. 47.	
LAR	15	WIKIPEDIA.com entry for "Cell Membrane." http://en.wikipedia.org/wiki/Cell_membrane - Accessed 2/14/06 . 3 pages.	

Examiner
SignatureDate
Considered

16 JULY 07

Unique citation designation number. *Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	ZHU, Yanhong
Art Unit	1614
Examiner Name	ROYDS, Leslie A.
Attorney Docket Number	13131-0292 (44378/287574)

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

16 JULY 07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IDS Filed May 24, 2007

PTO/SB/08a (08-03)


Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/650,110
		Filing Date	August 26, 2003
		First Named Inventor	ZHU, Yanhong
		Art Unit	1614
		Examiner Name	ROYDS, Leslie A.
Sheet 2 of 2	Attorney Docket Number	13131-0292 (44378/287574)	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LAR	3	DASS, et al., "Apolipoprotein A-1, Phospholipid Vesicles, and Cyclodextrins as Potential Anti-Atherosclerotic Drugs: Delivery, Pharmacokinetics, and Efficacy", Drug Delivery, 2000, pgs. 161-182, Vol. 7.	
LAR	4	ITO, et al., "Cholesterol-Sphingomyelin Interaction in Membrane and Apolipoprotein-Mediated Cellular Cholesterol Efflux", Journal of Lipid Research, 2000, pgs. 894-904, Vol. 41.	
LAR	5	KOSTNER, "Beyond LDL-Cholesterol or Enhancing Reverse Cholesterol Transport", pgs. 328-331. No date available	
LAR	6	SCANU, et al., "Solubility in Aqueous Solutions of Ethanol of the Small Molecular Weight Peptides of the Serum Lipoproteins", Analytical Biochemistry, 1971, pgs. 576-588, Vol. 44.	
LAR	7	TADEY, et al., "Chromatographic Techniques for the Isolation and Purification of Lipoproteins", Journal of Chromatography B., 1995, pgs. 237-253, Vol. 671.	
LAR	8	TRICERRI, et al., "Interaction of Apolipoprotein A-1 in Three Different Conformations with Palmitoyl Oleoyl Phosphatidylcholine Vesicles", Journal of Lipid Research, 2002, pgs. 187-197, Vol. 43.	

Examiner Signature		Date Considered	16 JULY 07
--------------------	---	-----------------	------------